Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407054 · ClinicalTrials.gov registry record · Phase 2
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT02407054 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 142 participants.
The verdict
NCT02407054, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Interventions
- DRUG Placebo
- DRUG Enzalutamide
- DRUG LY3023414
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2015-04-29 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02407054
The ClinicalTrials.gov registry entry for NCT02407054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02407054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02407054 about?
NCT02407054 is a clinical study titled "A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer". The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
What is the current status of trial NCT02407054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2015-04-29. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT02407054?
The interventions under investigation include: Placebo (DRUG), Enzalutamide (DRUG), LY3023414 (DRUG).
Who is sponsoring clinical trial NCT02407054?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.